Cargando…

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

PURPOSE: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an...

Descripción completa

Detalles Bibliográficos
Autores principales: Morillo Verdugo, Ramón, Ramírez Herráiz, Esther, Fernández-Del Olmo, Raquel, Roig Bonet, Montserrat, Valdivia García, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388740/
https://www.ncbi.nlm.nih.gov/pubmed/30863016
http://dx.doi.org/10.2147/PPA.S187983
_version_ 1783397808172171264
author Morillo Verdugo, Ramón
Ramírez Herráiz, Esther
Fernández-Del Olmo, Raquel
Roig Bonet, Montserrat
Valdivia García, María
author_facet Morillo Verdugo, Ramón
Ramírez Herráiz, Esther
Fernández-Del Olmo, Raquel
Roig Bonet, Montserrat
Valdivia García, María
author_sort Morillo Verdugo, Ramón
collection PubMed
description PURPOSE: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. METHODS: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making. RESULTS: The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). CONCLUSION: The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.
format Online
Article
Text
id pubmed-6388740
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63887402019-03-12 Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain Morillo Verdugo, Ramón Ramírez Herráiz, Esther Fernández-Del Olmo, Raquel Roig Bonet, Montserrat Valdivia García, María Patient Prefer Adherence Original Research PURPOSE: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. METHODS: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making. RESULTS: The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). CONCLUSION: The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence. Dove Medical Press 2019-02-13 /pmc/articles/PMC6388740/ /pubmed/30863016 http://dx.doi.org/10.2147/PPA.S187983 Text en © 2019 Morillo Verdugo et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Morillo Verdugo, Ramón
Ramírez Herráiz, Esther
Fernández-Del Olmo, Raquel
Roig Bonet, Montserrat
Valdivia García, María
Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title_full Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title_fullStr Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title_full_unstemmed Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title_short Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
title_sort adherence to disease-modifying treatments in patients with multiple sclerosis in spain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388740/
https://www.ncbi.nlm.nih.gov/pubmed/30863016
http://dx.doi.org/10.2147/PPA.S187983
work_keys_str_mv AT morilloverdugoramon adherencetodiseasemodifyingtreatmentsinpatientswithmultiplesclerosisinspain
AT ramirezherraizesther adherencetodiseasemodifyingtreatmentsinpatientswithmultiplesclerosisinspain
AT fernandezdelolmoraquel adherencetodiseasemodifyingtreatmentsinpatientswithmultiplesclerosisinspain
AT roigbonetmontserrat adherencetodiseasemodifyingtreatmentsinpatientswithmultiplesclerosisinspain
AT valdiviagarciamaria adherencetodiseasemodifyingtreatmentsinpatientswithmultiplesclerosisinspain